Full Press Release Details
Inspira and Bites Form Strategic Alliance to
Embed AI as a Core Standard Across Inspira's Global Ecosystem
RA'ANANA, Israel, October 22, 2025 -- Inspira Technologies
OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"),
a pioneer in innovative life-support and diagnostic technologies, today announced a strategic collaboration with Bites Learning Ltd. ("Bites"),
a leader in AI-based digital training and performance enablement solutions.
Through this collaboration, Bites' advanced AI-powered learning
and guidance platform will be embedded as a built-in standard across Inspira's ecosystem, including future versions of the INSPIRA
ART100 cardiopulmonary support system and the HYLA real-time blood sensor. The integration is designed to transform training, accelerate
onboarding, and enhance operational performance for hospitals, distributors, and users worldwide.
This collaboration creates a new AI-driven foundation for Inspira's
commercial operations - creating an intelligent training and support layer that simplifies onboarding, standardizes competencies, and
reduces support burdens across the Company's expanding customer base.
"By integrating Bites' AI engine directly into our ecosystem,
we are transforming how medical teams learn, operate, and scale proficiency," said Dagi Ben-Noon, Chief Executive Officer of Inspira
Technologies. "We expect this collaboration to significantly enhance operational consistency, expand adoption, and strengthen our
global execution - ultimately driving measurable shareholder value."
"Inspira is redefining digital transformation in medical devices,"
said Tal Nagler Almog, Chief Operating Officer of Bites. "Our AI-based platform will empower Inspira's global network with
real-time, personalized knowledge delivery, setting a new industry standard for training and compliance."
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing
in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. Food and Drug Administration -cleared
INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures
outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation
while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA , a proprietary blood sensor
platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining
of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape.
The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector
collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
About Bites Learning Ltd. Bites Learning Ltd. is a leading provider
of an AI-based digital training and knowledge platform. Its solution leverages adaptive microlearning and a personalized AI knowledge
feed to deliver on-demand, just-in-time guidance, helping global organizations accelerate onboarding, standardize competencies, and reduce
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of
the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the benefits
and advnatages of collaboration with Bites, the Company's expectation that this collaboration will expect this collaboration to
significantly enhance operational consistency, expand adoption, and strengthen our global execution, ultimately driving measurable shareholder
value, and that Bites' technology will empower Inspira's global network with real-time, personalized knowledge delivery and
set a new standard for the industry. These forward-looking statements and their implications are based solely on the current expectations
of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly
release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the
U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Inspira Technologies - Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485